Gynecology Book


Gonadotropin-releasing Hormone Agonist

Aka: Gonadotropin-releasing Hormone Agonist, GnRH agonist, Nafarelin Acetate, Synarel
  1. Indication
    1. Endometriosis
  2. Pathophysiology
    1. Potentiates Gonadotropin-releasing Hormone (GnRH)
    2. Results in hypoestrogenism or pseudo-Menopause
    3. Does not cause the same androgenic effects as Danazol
  3. Dosing: Nafarelin Acetate (Synarel)
    1. Synarel 200-400 micro-g intranasally bid
  4. Efficacy
    1. Effective at regression of lesions and relief of pain
    2. No proven effect on fertility
  5. Adverse effects
    1. Menopausal symptoms
      1. Hot Flashes
      2. Insomnia
      3. Emotional changes
    2. Bone density loss with prolonged use

Synarel (C0131793)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH D017274
French Synarel
English synarel, Synarel
Norwegian Synarel
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree